WO2002088170A3 - Cripto blocking antibodies and uses thereof - Google Patents

Cripto blocking antibodies and uses thereof Download PDF

Info

Publication number
WO2002088170A3
WO2002088170A3 PCT/US2002/011950 US0211950W WO02088170A3 WO 2002088170 A3 WO2002088170 A3 WO 2002088170A3 US 0211950 W US0211950 W US 0211950W WO 02088170 A3 WO02088170 A3 WO 02088170A3
Authority
WO
WIPO (PCT)
Prior art keywords
cripto
antibodies
bind
modulate
tumor growth
Prior art date
Application number
PCT/US2002/011950
Other languages
French (fr)
Other versions
WO2002088170A2 (en
Inventor
Michele Sanicola-Nadel
Kevin Williams
Susan Schiffer
Paul Rayhorn
Original Assignee
Biogen Inc
Michele Sanicola-Nadel
Kevin Williams
Susan Schiffer
Paul Rayhorn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27501437&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2002088170(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to CA2443840A priority Critical patent/CA2443840C/en
Priority to IL15857302A priority patent/IL158573A0/en
Priority to EP02731384A priority patent/EP1390389B1/en
Priority to DK02731384T priority patent/DK1390389T3/en
Priority to EA200301158A priority patent/EA007469B1/en
Priority to SK1443-2003A priority patent/SK14432003A3/en
Priority to EEP200300528A priority patent/EE200300528A/en
Application filed by Biogen Inc, Michele Sanicola-Nadel, Kevin Williams, Susan Schiffer, Paul Rayhorn filed Critical Biogen Inc
Priority to YU84903A priority patent/RS51635B/en
Priority to BRPI0209254-9A priority patent/BR0209254A/en
Priority to DE60230868T priority patent/DE60230868D1/en
Priority to MXPA03009797A priority patent/MXPA03009797A/en
Priority to HU0501113A priority patent/HUP0501113A3/en
Priority to SI200230804T priority patent/SI1390389T1/en
Priority to JP2002585468A priority patent/JP4307845B2/en
Priority to KR1020037014078A priority patent/KR100592357B1/en
Priority to JP2003580477A priority patent/JP2005520566A/en
Priority to DE60238559T priority patent/DE60238559D1/en
Priority to AT02807155T priority patent/ATE490981T1/en
Priority to PCT/US2002/031462 priority patent/WO2003083041A2/en
Priority to PT02807155T priority patent/PT1494693E/en
Priority to AU2002334799A priority patent/AU2002334799B2/en
Priority to EP02807155A priority patent/EP1494693B1/en
Priority to CA2480119A priority patent/CA2480119C/en
Priority to DK02807155.3T priority patent/DK1494693T3/en
Publication of WO2002088170A2 publication Critical patent/WO2002088170A2/en
Priority to US10/693,538 priority patent/US7531174B2/en
Priority to IS6999A priority patent/IS2662B/en
Priority to NO20034805A priority patent/NO20034805L/en
Priority to BG108363A priority patent/BG108363A/en
Publication of WO2002088170A3 publication Critical patent/WO2002088170A3/en
Priority to HK04101788.0A priority patent/HK1058935A1/en
Priority to US10/945,853 priority patent/US7582299B2/en
Priority to HK05105887.0A priority patent/HK1072381A1/en
Priority to US11/799,361 priority patent/US7674462B2/en
Priority to US12/317,476 priority patent/US8003763B2/en
Priority to US12/353,913 priority patent/US20090285818A1/en
Priority to JP2009020949A priority patent/JP2009161539A/en
Priority to US12/415,659 priority patent/US7888052B2/en
Priority to US13/213,499 priority patent/US8673303B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Abstract

The invention provides Cripto blocking antibodies, or biologically functional fragments thereof, and uses thereof. Antibodies which bind Cripto and modulate Cripto signaling are provided. Antibodies which bind Cripto and block the interaction between Cripto and ALK4 are provided. Antibodies which bind Cripto and modulate tumor growth are also provided. Antibodies which bind Cripto, modulate signaling, and modulate tumor growth are also provided. Antibodies which bind Cripto, block the interaction between Cripto and ALK4 and modulate tumor growth are provided. The invention also provides methods of using these antibodies in therapeutic, diagnostic, and research applications.
PCT/US2002/011950 2000-03-20 2002-04-17 Cripto blocking antibodies and uses thereof WO2002088170A2 (en)

Priority Applications (37)

Application Number Priority Date Filing Date Title
KR1020037014078A KR100592357B1 (en) 2001-04-26 2002-04-17 Cryptoblocking antibodies and uses thereof
EEP200300528A EE200300528A (en) 2001-04-26 2002-04-17 Cripto protein blocking antibodies and their use
EP02731384A EP1390389B1 (en) 2001-04-26 2002-04-17 Cripto blocking antibodies and uses thereof
DK02731384T DK1390389T3 (en) 2001-04-26 2002-04-17 Crypto-blocking antibodies and uses thereof
YU84903A RS51635B (en) 2001-04-26 2002-04-17 Cripto blocking antibodies and uses thereof
SK1443-2003A SK14432003A3 (en) 2001-04-26 2002-04-17 Cripto blocking antibodies and uses thereof
IL15857302A IL158573A0 (en) 2000-03-20 2002-04-17 Cripto blocking antibodies and uses thereof
CA2443840A CA2443840C (en) 2001-04-26 2002-04-17 Cripto blocking antibodies and uses thereof
EA200301158A EA007469B1 (en) 2001-04-26 2002-04-17 Cripto blocking antibodies and uses thereof
BRPI0209254-9A BR0209254A (en) 2001-04-26 2002-04-17 crypto blocking antibodies and uses thereof
DE60230868T DE60230868D1 (en) 2001-04-26 2002-04-17 CRIPTOBLOCKING ANTIBODIES AND THEIR USE
MXPA03009797A MXPA03009797A (en) 2001-04-26 2002-04-17 Cripto blocking antibodies and uses thereof.
HU0501113A HUP0501113A3 (en) 2001-04-26 2002-04-17 Cripto blocking antibodies and uses thereof
SI200230804T SI1390389T1 (en) 2001-04-26 2002-04-17 Cripto blocking antibodies and uses thereof
JP2002585468A JP4307845B2 (en) 2001-04-26 2002-04-17 Antibodies that block Cripto and uses thereof
DK02807155.3T DK1494693T3 (en) 2002-03-22 2002-10-01 Crypto-specific antibodies
AT02807155T ATE490981T1 (en) 2002-03-22 2002-10-01 CRIPTO-SPECIFIC ANTIBODIES
CA2480119A CA2480119C (en) 2002-03-22 2002-10-01 Cripto-specific antibodies
DE60238559T DE60238559D1 (en) 2002-03-22 2002-10-01 CRIPT-SPECIFIC ANTIBODIES
JP2003580477A JP2005520566A (en) 2002-03-22 2002-10-01 Cripto specific antibodies
PCT/US2002/031462 WO2003083041A2 (en) 2002-03-22 2002-10-01 Cripto-specific antibodies
PT02807155T PT1494693E (en) 2002-03-22 2002-10-01 Cripto-specific antibodies
AU2002334799A AU2002334799B2 (en) 2001-04-26 2002-10-01 Cripto-specific antibodies
EP02807155A EP1494693B1 (en) 2002-03-22 2002-10-01 Cripto-specific antibodies
US10/693,538 US7531174B2 (en) 2001-04-26 2003-10-23 Cripto blocking antibodies and uses thereof
IS6999A IS2662B (en) 2001-04-26 2003-10-24 Antibodies that block the Cripto protein and their use
NO20034805A NO20034805L (en) 2001-04-26 2003-10-27 CRIPTO-blocking antibody and its use
BG108363A BG108363A (en) 2001-04-26 2003-11-14 Cripto blocking antibodies and use thereof
HK04101788.0A HK1058935A1 (en) 2001-04-26 2004-03-11 Cripto blocking antibodies and uses thereof
US10/945,853 US7582299B2 (en) 2001-04-26 2004-09-20 Cripto-specific antibodies
HK05105887.0A HK1072381A1 (en) 2002-03-22 2005-07-11 Cripto-specific antibodies cripto-specific
US11/799,361 US7674462B2 (en) 2001-04-26 2007-04-30 Cripto blocking antibodies and uses thereof
US12/317,476 US8003763B2 (en) 2001-04-26 2008-12-22 Cripto blocking antibodies and uses thereof
US12/353,913 US20090285818A1 (en) 2001-04-26 2009-01-14 Cripto Blocking Antibodies and Uses Thereof
JP2009020949A JP2009161539A (en) 2002-03-22 2009-01-30 Cripto-specific antibody
US12/415,659 US7888052B2 (en) 2001-04-26 2009-03-31 Cripto blocking antibodies and uses thereof
US13/213,499 US8673303B2 (en) 2001-04-26 2011-08-19 Cripto blocking antibodies and uses thereof

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US28678201P 2001-04-26 2001-04-26
US60/286,782 2001-04-26
US29302001P 2001-05-17 2001-05-17
US60/293,020 2001-05-17
US30109101P 2001-06-26 2001-06-26
US60/301,091 2001-06-26
US36700202P 2002-03-22 2002-03-22
US60/367,002 2002-03-22

Related Child Applications (3)

Application Number Title Priority Date Filing Date
PCT/US2002/031462 Continuation WO2003083041A2 (en) 2001-04-26 2002-10-01 Cripto-specific antibodies
US10/693,538 Continuation US7531174B2 (en) 2001-04-26 2003-10-23 Cripto blocking antibodies and uses thereof
US10/945,853 Continuation US7582299B2 (en) 2001-04-26 2004-09-20 Cripto-specific antibodies

Publications (2)

Publication Number Publication Date
WO2002088170A2 WO2002088170A2 (en) 2002-11-07
WO2002088170A3 true WO2002088170A3 (en) 2003-12-24

Family

ID=27501437

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/011950 WO2002088170A2 (en) 2000-03-20 2002-04-17 Cripto blocking antibodies and uses thereof

Country Status (34)

Country Link
US (6) US7531174B2 (en)
EP (3) EP1974749B1 (en)
JP (4) JP4307845B2 (en)
KR (1) KR100592357B1 (en)
CN (1) CN100352501C (en)
AR (3) AR037223A1 (en)
AT (2) ATE533508T1 (en)
BG (1) BG108363A (en)
BR (1) BR0209254A (en)
CA (2) CA2443840C (en)
CL (1) CL2009002199A1 (en)
CY (1) CY1108960T1 (en)
CZ (1) CZ20033208A3 (en)
DE (1) DE60230868D1 (en)
DK (1) DK1390389T3 (en)
EA (1) EA007469B1 (en)
EE (1) EE200300528A (en)
ES (1) ES2321065T3 (en)
GE (1) GEP20074091B (en)
HK (1) HK1058935A1 (en)
HU (1) HUP0501113A3 (en)
IS (1) IS2662B (en)
MX (1) MXPA03009797A (en)
MY (2) MY157382A (en)
NO (1) NO20034805L (en)
NZ (1) NZ566268A (en)
PL (1) PL207087B1 (en)
PT (1) PT1390389E (en)
RS (2) RS51635B (en)
SG (1) SG157951A1 (en)
SI (1) SI1390389T1 (en)
SK (1) SK14432003A3 (en)
TR (1) TR200301846T2 (en)
WO (1) WO2002088170A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9562049B2 (en) 2012-12-21 2017-02-07 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US9567340B2 (en) 2012-12-21 2017-02-14 Medimmune Limited Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPR395801A0 (en) 2001-03-26 2001-04-26 Austin Research Institute, The Antibodies against cancer
US20090123470A1 (en) * 2001-03-26 2009-05-14 The Macfarlane Burnet Istitute For Medical Research And Public Health Ltd. Antibodies Against Cancer
EA007469B1 (en) 2001-04-26 2006-10-27 Байоджен Айдек Эмэй Инк. Cripto blocking antibodies and uses thereof
US7582299B2 (en) 2001-04-26 2009-09-01 Biogen Idec Ma Inc. Cripto-specific antibodies
EP1494693B1 (en) * 2002-03-22 2010-12-08 Biogen Idec MA Inc. Cripto-specific antibodies
JP5068072B2 (en) 2003-06-27 2012-11-07 バイオジェン・アイデック・エムエイ・インコーポレイテッド Modified binding molecule comprising a linking peptide
DK1670511T3 (en) * 2003-09-15 2009-11-23 Res Dev Foundation Crypto-antagonism of activin and TGF-B signaling
BR122018071808B8 (en) 2003-11-06 2020-06-30 Seattle Genetics Inc conjugate
EP2385069A3 (en) 2003-11-12 2012-05-30 Biogen Idec MA Inc. Neonatal Fc rReceptor (FcRn)- binding polypeptide variants, dimeric Fc binding proteins and methods related thereto
BRPI0510883B8 (en) 2004-06-01 2021-05-25 Genentech Inc drug-antibody conjugate compound, pharmaceutical composition, method of manufacturing a drug-antibody conjugate compound, and uses of a formulation, a drug-antibody conjugate and a chemotherapeutic agent, and a combination
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
RU2412947C2 (en) 2004-09-23 2011-02-27 Дженентек, Инк. Antibodies, constructed on cysteine basis and their conjugates
WO2006074399A2 (en) 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
KR20070100346A (en) 2005-01-05 2007-10-10 바이오겐 아이덱 엠에이 인코포레이티드 Cripto binding molecules
WO2008014426A2 (en) * 2006-07-28 2008-01-31 Children's Memorial Hospital Methods of inhibiting tumor cell aggressiveness using the microenvironment of human embryonic stem cells
US20100330081A1 (en) * 2007-06-01 2010-12-30 Biogen Idec Ma Inc. Cripto binding molecules
US20110123443A1 (en) * 2008-04-21 2011-05-26 Merck & Co., Inc. Pancreatic beta-cell mass biomarker
JP5805538B2 (en) * 2008-11-07 2015-11-04 リサーチ ディベロップメント ファウンデーション Compositions and methods for inhibiting Cripto / GSP78 complex formation and signaling
IN2012DN03025A (en) 2009-09-09 2015-07-31 Ct Se Llc
TWI540136B (en) 2010-04-15 2016-07-01 梅迪繆思有限公司 Pyrrolobenzodiazepines and conjugates thereof
SG185428A1 (en) 2010-06-08 2012-12-28 Genentech Inc Cysteine engineered antibodies and conjugates
JP5889912B2 (en) 2010-11-17 2016-03-22 ジェネンテック， インコーポレイテッド Alaninyl maytansinol antibody conjugate
EP3138581B1 (en) 2011-03-17 2019-01-02 The University of Birmingham Re-directed immunotherapy
CA2833477A1 (en) 2011-04-21 2012-10-26 Seattle Genetics, Inc. Novel binder-drug conjugates (adcs) and their use
JP5987053B2 (en) 2011-05-12 2016-09-06 ジェネンテック， インコーポレイテッド Multiple reaction monitoring LC-MS / MS method for detecting therapeutic antibodies in animal samples using framework signature peptides
WO2013012733A1 (en) 2011-07-15 2013-01-24 Biogen Idec Ma Inc. Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto
CN103987407B (en) 2011-10-14 2016-08-24 麦迪穆有限责任公司 Pyrrolobenzodiazepines Zhuo and conjugate thereof
WO2013130093A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
AU2013328628B2 (en) 2012-10-12 2016-12-15 Adc Therapeutics Sa Pyrrolobenzodiazepine-anti-CD22 antibody conjugates
DK2906296T3 (en) 2012-10-12 2018-05-22 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
US9931414B2 (en) 2012-10-12 2018-04-03 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
US10695433B2 (en) 2012-10-12 2020-06-30 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
SI2906253T1 (en) 2012-10-12 2018-11-30 Adc Therapeutics Sa Pyrrolobenzodiazepine - anti-psma antibody conjugates
RS58921B1 (en) 2012-10-12 2019-08-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
ES2680153T3 (en) 2012-10-12 2018-09-04 Adc Therapeutics Sa Anti-PSMA-pyrrolobenzodiazepine antibody conjugates
EA027910B1 (en) 2013-03-13 2017-09-29 Медимьюн Лимитед Pyrrolobenzodiazepines and conjugates thereof
KR102066318B1 (en) 2013-03-13 2020-01-14 메디뮨 리미티드 Pyrrolobenzodiazepines and conjugates thereof
MX362970B (en) 2013-03-13 2019-02-28 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof.
WO2015023355A1 (en) 2013-08-12 2015-02-19 Genentech, Inc. 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
US9956299B2 (en) 2013-10-11 2018-05-01 Medimmune Limited Pyrrolobenzodiazepine—antibody conjugates
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
EP3054985B1 (en) 2013-10-11 2018-12-26 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
US10010624B2 (en) 2013-10-11 2018-07-03 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
CR20160271A (en) 2013-12-16 2016-12-02 Genentech Inc PEPTIDOMETIC COMPOUNDS AND THEIR ANTIBODY-DRUG CONJUGATES
CA2929565A1 (en) 2013-12-16 2015-06-25 Genentech, Inc. 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
WO2015095223A2 (en) 2013-12-16 2015-06-25 Genentech, Inc. Peptidomimetic compounds and antibody-drug conjugates thereof
BR112016014830A2 (en) 2013-12-23 2017-09-19 Bayer Pharma AG ANTIBODY DRUG CONJUGATES (ADCS) WITH KSP INHIBITORS
WO2016037644A1 (en) 2014-09-10 2016-03-17 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
SG11201701128YA (en) 2014-09-12 2017-03-30 Genentech Inc Cysteine engineered antibodies and conjugates
CN106714844B (en) 2014-09-12 2022-08-05 基因泰克公司 Anthracycline disulfide intermediates, antibody-drug conjugates and methods
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
JP2017533887A (en) 2014-09-17 2017-11-16 ジェネンテック， インコーポレイテッド Pyrrolobenzodiazepines and their antibody disulfide conjugates
BR112017011111A2 (en) 2014-11-25 2017-12-26 Adc Therapeutics Sa pyrrolobenzodiazepine-antibody conjugates
EP3226909A1 (en) 2014-12-03 2017-10-11 Genentech, Inc. Quaternary amine compounds and antibody-drug conjugates thereof
AU2016245328A1 (en) * 2015-04-07 2017-10-12 Paranta Biosciences Limited A method of treating neoplasias
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
SG10201908685QA (en) 2015-06-22 2019-10-30 Bayer Pharma AG Antibody drug conjugates (adcs) and antibody prodrug conjugates (apdcs) with enzymatically cleavable groups
MA43345A (en) 2015-10-02 2018-08-08 Hoffmann La Roche PYRROLOBENZODIAZEPINE ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
WO2017060322A2 (en) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Ptefb-inhibitor-adc
MA43354A (en) 2015-10-16 2018-08-22 Genentech Inc CONJUGATE DRUG CONJUGATES WITH CLOUDY DISULPHIDE
MA45326A (en) 2015-10-20 2018-08-29 Genentech Inc CALICHEAMICIN-ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
PE20181852A1 (en) 2016-03-24 2018-12-03 Bayer Pharma AG CYTOTOXIC PHARMACEUTICAL DRUGS HAVING ENZYMATICALLY DISCENDABLE GROUPS
CN108700598A (en) 2016-03-25 2018-10-23 豪夫迈·罗氏有限公司 The drug of the total antibody of multichannel and antibody conjugate quantifies measuring method
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
JP2019522633A (en) 2016-05-20 2019-08-15 ジェネンテック， インコーポレイテッド PROTAC antibody conjugates and methods of use
WO2017205741A1 (en) 2016-05-27 2017-11-30 Genentech, Inc. Bioanalytical method for the characterization of site-specific antibody-drug conjugates
EP3464280B1 (en) 2016-06-06 2021-10-06 F. Hoffmann-La Roche AG Silvestrol antibody-drug conjugates and methods of use
US11001636B2 (en) 2016-06-15 2021-05-11 Bayer Pharma Aktiengesellschaft Specific antibody-drug-conjugates (ADCs) with KSP inhibitors and anti-CD123-antibodies
WO2018031662A1 (en) 2016-08-11 2018-02-15 Genentech, Inc. Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof
JP7050770B2 (en) 2016-10-05 2022-04-08 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Method for preparing antibody drug conjugate
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
US20190351066A1 (en) 2016-12-21 2019-11-21 Bayer Aktiengesellschaft Prodrugs of cytotoxic active agents having enzymatically cleavable groups
CA3047522A1 (en) 2016-12-21 2018-06-28 Bayer Pharma Aktiengesellschaft Specific antibody drug conjugates (adcs) having ksp inhibitors
CA3047489A1 (en) 2016-12-21 2018-06-28 Bayer Pharma Aktiengesellschaft Antibody drug conjugates (adcs) having enzymatically cleavable groups
US11160872B2 (en) 2017-02-08 2021-11-02 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
JP2020517609A (en) 2017-04-18 2020-06-18 メディミューン リミテッド Pyrrolobenzodiazepine complex
KR20190141666A (en) 2017-04-20 2019-12-24 에이디씨 테라퓨틱스 에스에이 Combination Therapy with Anti-AXL Antibody-Drug Conjugates
MX2019015042A (en) 2017-06-14 2020-08-06 Adc Therapeutics Sa Dosage regimes for the administration of an anti-cd19 adc.
CN111065638B (en) 2017-08-18 2021-04-09 麦迪穆有限责任公司 Pyrrolobenzodiazepine conjugates
BR112020004307A2 (en) 2017-09-20 2020-11-10 Ph Pharma Co., Ltd. tailanestatin analogues
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
JOP20200268A1 (en) 2018-06-01 2020-10-26 Eisai R&D Man Co Ltd Splicing modulator antibody-drug conjugates and methods of use
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
CN113056287A (en) 2018-10-24 2021-06-29 豪夫迈·罗氏有限公司 Conjugated chemical degradation inducers and methods of use
WO2020123275A1 (en) 2018-12-10 2020-06-18 Genentech, Inc. Photocrosslinking peptides for site specific conjugation to fc-containing proteins
TW202039007A (en) 2018-12-13 2020-11-01 日商衛材R&D企管股份有限公司 Herboxidiene splicing modulator antibody-drug conjugates and methods of use
CA3120800A1 (en) 2018-12-17 2020-06-25 Revitope Limited Twin immune cell engager
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5264557A (en) * 1991-08-23 1993-11-23 The United States Of America As Represented By The Department Of Health And Human Services Polypeptide of a human cripto-related gene, CR-3
WO2000063693A1 (en) * 1999-04-20 2000-10-26 Kokolus William J Improved method of identifying and locating immunobiologically-active linear peptides

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ207394A (en) * 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5208020A (en) * 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5780029A (en) 1989-11-14 1998-07-14 New York Medical College Antidiotypic monoclonal antibodies for treatment of melanoma
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5256643A (en) 1990-05-29 1993-10-26 The Government Of The United States Human cripto protein
ES2246502T3 (en) 1990-08-29 2006-02-16 Genpharm International, Inc. TRANSGENIC NON-HUMAN ANIMALS ABLE TO PRODUCE HETEROLOGICAL ANTIBODIES.
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US6063379A (en) 1993-12-09 2000-05-16 Centro De Inmunologia Molecular Anti-idiotypic monoclonal antibodies and compositions including the anti-idiotypic monoclonal antibodies
US5981215A (en) * 1995-06-06 1999-11-09 Human Genome Sciences, Inc. Human criptin growth factor
US6207153B1 (en) * 1996-05-22 2001-03-27 Viventia Biotech, Inc. Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers
IL125608A0 (en) 1998-07-30 1999-03-12 Yeda Res & Dev Tumor associated antigen peptides and use of same as anti-tumor vaccines
KR100849443B1 (en) 1998-12-23 2008-07-31 화이자 인크. Human monoclonal antibodies to ctla-4
AU3316600A (en) * 1999-02-22 2000-09-21 Torben F. Orntoft Gene expression in bladder tumors
AU754808B2 (en) 1999-03-30 2002-11-28 Amgen Fremont Inc. Method for preparing Monoclonal Antibody
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
JP2001046066A (en) 1999-08-03 2001-02-20 Kyowa Hakko Kogyo Co Ltd Antibody against human vegf receptor kdr having new complementary determining region
ATE400587T1 (en) 1999-10-29 2008-07-15 Genentech Inc ANTIBODIES DIRECTED AGAINST THE PROSTATE STEM CELL ANTIGEN (PSCA) AND THEIR USE
US6663613B1 (en) 2000-01-25 2003-12-16 Bacchus Vascular, Inc. System and methods for clot dissolution
US6989145B2 (en) * 2000-03-03 2006-01-24 Kyowa Hakko Kogyo Co., Ltd. Recombinant antibody and antibody fragment
US6333410B1 (en) * 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
GB0020953D0 (en) 2000-08-24 2000-10-11 Smithkline Beecham Biolog Vaccine
AU2001292724B2 (en) 2000-09-18 2005-05-26 Biogen Idec Ma Inc. CRIPTO mutant and uses thereof
EP1370869B1 (en) 2001-01-26 2006-12-27 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Detection and quantification of cripto-1
EA007388B1 (en) 2001-01-29 2006-10-27 Идек Фармасьютикалз Корпорейшн Modified antibodies and methods of use
US7319139B2 (en) 2001-01-29 2008-01-15 Biogen Idec, Inc. TAG-72 specific CH2 domain deleted antibodies
AUPR395801A0 (en) * 2001-03-26 2001-04-26 Austin Research Institute, The Antibodies against cancer
US7582299B2 (en) * 2001-04-26 2009-09-01 Biogen Idec Ma Inc. Cripto-specific antibodies
EA007469B1 (en) * 2001-04-26 2006-10-27 Байоджен Айдек Эмэй Инк. Cripto blocking antibodies and uses thereof
NZ573831A (en) * 2001-09-18 2010-07-30 Genentech Inc Compositions and methods for the diagnosis and treatment of tumor, particularly breast tumor - TAT193
US20040014690A1 (en) * 2002-02-13 2004-01-22 Zhenkun Ma Macrolides with activity against methicillin-resistant staphylococcus aureus
EP1494693B1 (en) * 2002-03-22 2010-12-08 Biogen Idec MA Inc. Cripto-specific antibodies
DK1670511T3 (en) * 2003-09-15 2009-11-23 Res Dev Foundation Crypto-antagonism of activin and TGF-B signaling
KR20070100346A (en) 2005-01-05 2007-10-10 바이오겐 아이덱 엠에이 인코포레이티드 Cripto binding molecules
CN101479391A (en) 2006-04-28 2009-07-08 比奥根艾迪克Ma公司 Composition and methods for the detection of CRIPTO-3

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5264557A (en) * 1991-08-23 1993-11-23 The United States Of America As Represented By The Department Of Health And Human Services Polypeptide of a human cripto-related gene, CR-3
WO2000063693A1 (en) * 1999-04-20 2000-10-26 Kokolus William J Improved method of identifying and locating immunobiologically-active linear peptides

Non-Patent Citations (15)

* Cited by examiner, † Cited by third party
Title
BIANCO ET AL.: "Cripto-1 indirectly stimulates the tyrosine phosphorylation of erb B-4 through a novel receptor", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 274, 26 March 1999 (1999-03-26), pages 8624 - 8629, XP002201894 *
BRANDT ET AL.: "Identification and biological characterization of an epidermal growth factor-related protein:Cripto-1", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 269, 24 June 1994 (1994-06-24), pages 17320 - 17328, XP000910201 *
CICCODICOLA ET AL.: "Molecular characterization of a gene of the 'EGF family' expressed in undifferentiated human NTERA2 teratocarcinoma cells", THE EMBO JOURNAL, vol. 8, 1989, pages 1987 - 1991, XP000872594 *
DATABASE BIOSIS [online] DUBLIN ET AL.: "Amphiregulin and cripto overexpression in breast cancer relationship with prognosis and clinical and molecular variables", XP002967856, accession no. STN Database accession no. 1995:456402 *
DATABASE BIOSIS [online] SAEKI ET AL.: "Expression of cripto-1 in human colorectal adenomas and carcinomas is related to the degree of dysplasia", XP002967857, accession no. STN Database accession no. 1995:111501 *
DATABASE BIOSIS [online] SAEKI ET AL.: "Immunohistochemical detection of cripto-1, amphiregulin and transforming growth factor alpha in human gastric carcinomas and intestinal metaplasias", XP002967858, accession no. STN Database accession no. 1995:110701 *
DATABASE MEDLINE [online] CIARDIELLO ET AL.: "Inhibition of Cripto expression and tumorigenicity in human colon cancer cells by antisense RNA and oligodeoxynucleotides", XP002967859, accession no. STN Database accession no. 94134427 *
DATABASE SCISEARCH [online] NORMANNO ET AL.: "Expression of amphiregulin, Cripto-1 and heregulin-alpha in human breast-cancer cells", XP002967860, accession no. STN Database accession no. 93:334632 *
EBERT ET AL.: "Cripto-1 induces phosphatidylinositol 3'-kinase-dependent phosphorylation of AKT and glycogen synthase kinase 3beta in human cervical carcinoma cells", CANCER RESEARCH, vol. 59, 15 September 1999 (1999-09-15), pages 4502 - 4505, XP002967855 *
INTERNATIONAL JOURNAL OF ONCOLOGY, vol. 2, 1993, pages 903 - 911 *
INTERNATIONAL JOURNAL OF ONCOLOGY, vol. 5, 1994, pages 215 - 223 *
INTERNATIONAL JOURNAL OF ONCOLOGY, vol. 5, 1994, pages 445 - 451 *
INTERNATIONAL JOURNAL OF ONCOLOGY, vol. 7, 1995, pages 617 - 622 *
KANNAN ET AL.: "Cripto enhances the tyrosin phosphorylation of she and activates mitogen-activated protein kinase (MAPK) in mammary epithelial cells", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 272, 7 February 1997 (1997-02-07), pages 3330 - 3335, XP002967854 *
ONCOGENE, vol. 9, 1994, pages 291 - 298 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9562049B2 (en) 2012-12-21 2017-02-07 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US9567340B2 (en) 2012-12-21 2017-02-14 Medimmune Limited Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases

Also Published As

Publication number Publication date
CA2715570A1 (en) 2002-11-07
SK14432003A3 (en) 2004-07-07
JP2010163438A (en) 2010-07-29
NO20034805L (en) 2003-12-23
GEP20074091B (en) 2007-04-25
HK1058935A1 (en) 2004-06-11
EP2316486A3 (en) 2011-09-07
AR072554A2 (en) 2010-09-08
PT1390389E (en) 2009-04-03
BR0209254A (en) 2006-10-03
ATE533508T1 (en) 2011-12-15
US20120195912A1 (en) 2012-08-02
EP1974749A1 (en) 2008-10-01
JP2005314436A (en) 2005-11-10
US20080166341A1 (en) 2008-07-10
US20090286265A1 (en) 2009-11-19
CA2443840A1 (en) 2002-11-07
MY150237A (en) 2013-12-31
EP1390389B1 (en) 2009-01-14
EP1390389A2 (en) 2004-02-25
EP2316486A2 (en) 2011-05-04
SI1390389T1 (en) 2009-06-30
BG108363A (en) 2004-09-30
IS2662B (en) 2010-08-15
IS6999A (en) 2003-10-24
WO2002088170A2 (en) 2002-11-07
EP1974749B1 (en) 2011-11-16
RS51635B (en) 2011-08-31
CL2009002199A1 (en) 2010-05-07
EE200300528A (en) 2004-08-16
YU84903A (en) 2006-05-25
RS20110024A (en) 2011-08-31
US20040146940A1 (en) 2004-07-29
MXPA03009797A (en) 2004-01-29
PL207087B1 (en) 2010-10-29
HUP0501113A2 (en) 2007-05-02
SG157951A1 (en) 2010-01-29
CA2443840C (en) 2010-10-26
NO20034805D0 (en) 2003-10-27
ATE420659T1 (en) 2009-01-15
DK1390389T3 (en) 2009-04-20
ES2321065T3 (en) 2009-06-02
US20100202962A1 (en) 2010-08-12
JP4307845B2 (en) 2009-08-05
CZ20033208A3 (en) 2004-03-17
NZ566268A (en) 2009-09-25
US8003763B2 (en) 2011-08-23
DE60230868D1 (en) 2009-03-05
CN100352501C (en) 2007-12-05
AR037223A1 (en) 2004-11-03
EA007469B1 (en) 2006-10-27
JP4575983B2 (en) 2010-11-04
PL373513A1 (en) 2005-09-05
KR20040028744A (en) 2004-04-03
JP2009108100A (en) 2009-05-21
MY157382A (en) 2016-06-15
JP2004534020A (en) 2004-11-11
US20090285818A1 (en) 2009-11-19
TR200301846T2 (en) 2006-10-26
HUP0501113A3 (en) 2007-12-28
CY1108960T1 (en) 2014-07-02
KR100592357B1 (en) 2006-06-22
EP1390389A4 (en) 2004-09-22
US7531174B2 (en) 2009-05-12
AR077759A2 (en) 2011-09-21
US7888052B2 (en) 2011-02-15
US8673303B2 (en) 2014-03-18
CN1606453A (en) 2005-04-13
US7674462B2 (en) 2010-03-09
EA200301158A1 (en) 2005-06-30

Similar Documents

Publication Publication Date Title
WO2002088170A3 (en) Cripto blocking antibodies and uses thereof
WO2003083041A8 (en) Cripto-specific antibodies
HK1076113A1 (en) Specific binding agents of human angiopoietin-2
MY136095A (en) Use of human anti-ctla-4 antibodies for treatment of cancer
HK1048831A1 (en) Human ctla-4 antibodies and their uses
ZA200200097B (en) Antibody molecules having specificity for human tumor necrosis factor alpha, and use thereof.
AU2001235006A1 (en) Prophylactic and therapeutic monoclonal antibodies
MXPA03008739A (en) Ganglioside-associated recombinant antibodies and the use thereof in the diagnosis and treatment of tumours.
IL163902A0 (en) Antibodies against cancer antigen tmeff2 and uses thereof
ZA200205191B (en) LIV-1 related protein, polynucleotides encoding the same and use thereof for treatment of cancer.
WO2003104425A3 (en) Novel stable anti-cd22 antibodies
WO2002026819A3 (en) Recombinant bcg vaccines for the prevention and treatment of cancer
WO2001007479A3 (en) Fragments of cellular prion protein and methods useful in the diagnosis and treatment of prion diseases
WO2002066492A3 (en) Human adrenomedullin-specific antibody, pharmaceutical composition containing same, therapeutic uses thereof
ATE490981T1 (en) CRIPTO-SPECIFIC ANTIBODIES
TW200635951A (en) Specific binding agents of human angiopoietin-2
UA32280A (en) Technique for applying ileocolonic side-to-side anastomosis

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: P-849/03

Country of ref document: YU

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 10693538

Country of ref document: US

Ref document number: 2443840

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2003/009797

Country of ref document: MX

Ref document number: 373513

Country of ref document: PL

Ref document number: 1-2003-501076

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 2002585468

Country of ref document: JP

Ref document number: 2003/01846

Country of ref document: TR

Ref document number: 1020037014078

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 01888/DELNP/2003

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 200308862

Country of ref document: ZA

ENP Entry into the national phase

Ref document number: 10836302

Country of ref document: BG

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 14432003

Country of ref document: SK

WWE Wipo information: entry into national phase

Ref document number: 529710

Country of ref document: NZ

Ref document number: 2002731384

Country of ref document: EP

Ref document number: PV2003-3208

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 2002303364

Country of ref document: AU

Ref document number: 200301158

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 7196

Country of ref document: GE

Ref document number: 5415

Country of ref document: GE

WWE Wipo information: entry into national phase

Ref document number: 028128877

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2002731384

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV2003-3208

Country of ref document: CZ

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: PI0209254

Country of ref document: BR